About Us

Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
My Watchlist
Indicators
Local Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Immunic, Inc. - Common Stock (NQ:IMUX)

6.660 -0.230 (-3.34%)
Delayed Quote Updated: 4:00 PM EDT, Oct 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Immunic, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Immunic CMO discusses role of clinical trials in biotech development for Clinical Trials Day
Immunic Inc (NASDAQ:IMUX) chief medical officer Dr Andreas Muehler discusses the importance of clinical trials in the biotech industry to mark Clinical Trials Day on May 20. 
Via TheNewswire.com
News headline image
Immunic CMO discusses role of clinical trials in biotech development for Clinical Trials Day
Immunic CMO discusses role of clinical trials in biotech development for Clinical Trials Day 
Via News Direct
News headline image
Immunic chief medical officer discusses promising treatments to mark World IBD Day
Immunic chief medical officer discusses promising treatments to mark World IBD Day 
Via News Direct
Immunic chief medical officer discusses promising treatments to mark World IBD Day
Immunic Inc (NASDAQ:IMUX) chief medical officer Dr Andreas Muehler discusses Inflammatory Bowel Disease (IBD) with Proactive's Stephen Gunnion to mark World IBD Day on May 19. 
Via TheNewswire.com
News headline image
Immunic highlights IMU-856 gastrointestinal candidate to mark International Celiac Day
Immunic highlights IMU-856 gastrointestinal candidate to mark International Celiac Day 
Via News Direct
Immunic highlights IMU-856 gastrointestinal candidate to mark International Celiac Day
Immunic Inc (NASDAQ:IMUX) chief scientific officer Hella Kohlhof joined Proactive's Stephen Gunnion on International Celiac Day, in the middle of Celiac Disease Awareness Month, to discuss the disease... 
Via TheNewswire.com
News headline image
IMUX Stock Earnings: Immunic Misses EPS for Q1 2024 ↗
IMUX stock results show that Immunic missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
Immunic's Earnings Outlook ↗
 
Via Benzinga
News headline image
Immunic: Q3 Earnings Insights ↗
 
Via Benzinga
News headline image
Immunic CEO Dr Daniel Vitt discusses key Q1 advances and upcoming milestones
Immunic CEO Dr Daniel Vitt discusses key Q1 advances and upcoming milestones 
Via News Direct
Topics Intellectual Property
Immunic CEO Dr Daniel Vitt discusses key Q1 advances and upcoming milestones
Immunic Inc (NASDAQ:IMUX) CEO Dr Daniel Vitt takes Proactive's Stephen Gunnion through the company's first-quarter achievements and upcoming milestones for its clinical pipeline of orally administered,... 
Via TheNewswire.com
Topics Intellectual Property
News headline image
Immunic Phase 2 EMPhASIS trial data highlighted in peer-reviewed neurology journal
Immunic Phase 2 EMPhASIS trial data highlighted in peer-reviewed neurology journal 
Via News Direct
Immunic Phase 2 EMPhASIS trial data highlighted in peer-reviewed neurology journal
Immunic Inc (NASDAQ:IMUX) CEO Dr Daniel Vitt joined Proactive's Stephen Gunnion with news of the publication of extended data from the Phase 2 EMPhASIS trial of vidofludimus calcium in... 
Via TheNewswire.com
Immunic CMO discusses complexities of multiple sclerosis to mark MS Awareness Month
--News Direct-- 
Via News Direct
News headline image
A Preview Of Immunic's Earnings ↗
 
Via Benzinga
Immunic "super excited" about latest PMS trial data
--News Direct-- 
Via News Direct
Immunic CMO discusses complexities of multiple sclerosis to mark MS Awareness Month
Immunic Inc (NASDAQ:IMUX) Chief Medical Officer Dr Andreas Muehler discusses the complexities of multiple sclerosis (MS) during an interview with Proactive's Stephen Gunnion to mark MS Awareness Month,... 
Via TheNewswire.com
News headline image
Immunic And 2 Other Stocks Under $2 Insiders Are Buying ↗
The Dow Jones index closed lower by over 20 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Topics Stocks
News headline image
What's Going On With Immunic Stock? ↗
Immunic, Inc. (NASDAQ: IMUX) shares are roughly flat following strength early Friday after the company announced a three-tranche private placement of up to $240 million. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗
Pre-market stock movers are worth checking on Friday as we lay out all of the biggest stories worth keeping tabs on this morning! 
Via InvestorPlace
Immunic CSO hails "great" progress with MS program
--News Direct-- 
Via News Direct
Immunic CSO hails "great" progress with MS program
Immunic Inc (NASDAQ:IMUX) Chief Scientific Officer Hella Kohlhof speaks to Thomas Warner at the Proactive London after returning from MSMilan2023, the 9th Joint ECTRIMS-ACTRIMS meeting. She shares some... 
Via TheNewswire.com
Immunic "super excited" about latest PMS trial data
Immunic Inc (NASDAQ:IMUX) President and CEO Dr Daniel Vitt speaks to Thomas Warner from Proactive after the biotechnology company announced encouraging interim data from its phase II CALLIPER trial... 
Via TheNewswire.com
News headline image
Why Startek Shares Are Trading Higher By 29%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers SuperCom Ltd. (NASDAQ: SPCB) shares jumped 89% to $0.6805, after falling 13% on Monday. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Multiple Sclerosis Impacts 1M People In US - Immunic Reveals 'Positive' Data From Nerve Disorder Candidate ↗
Immunic Inc (NASDAQ: IMUX) announced interim data from its phase 2 CALLIPER trial of nuclear receptor-related 1 (Nurr1) activator, vidofludimus calcium (IMU-838), in patients with  
Via Benzinga
News headline image
Why Immunic Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket ↗
Gainers SuperCom Ltd. (NASDAQ: SPCB) shares rose 78.4% to $0.6425 in pre-market trading, after falling 13% on Monday. 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗
It's time to dive into the biggest pre-market stock movers with all the most recent news moving shares on Tuesday morning! 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.